IgG Antibodies Generation and Side Effects Caused by Ad5-nCoV Vaccine (CanSino Biologics) and BNT162b2 Vaccine (Pfizer/BioNTech) among Mexican Population

Abstract

SARS-CoV-2 has rapidly generated a pandemic. Vaccines are currently being rolled out to control the viral spread and prevent deaths. Emergency vaccines, using new platforms, have been approved. Their effectiveness, safety and immunogenicity in different populations are not fully known. This study aimed to discover the immunogenicity of the messenger ribonucleic acid (mRNA) BNT162b2 and adenovirus vector Ad5-nCoV vaccines through IgG antibody generation against subunit 1 of protein S (S1 IgG) and assess the side effects of the vaccines. A total of 115 vaccinated people were included, 61 of whom received the BNT162b2 vaccine, while 54 received Ad5-nCoV. Measurements of S1 IgG antibodies were carried out using the enzyme-linked immunosorbent assay (ELISA) technique. The BNT162b2 vaccine generated S1 IgG antibodies in 80.3% of the participants after the first dose. The number of seropositive participants increased to 98.36% with the administration of the second dose. The Ad5-nCoV vaccine generated S1 IgG antibodies in 88.89% of those vaccinated. Women generated more antibodies when administered either vaccine. There were no serious adverse effects from vaccination. In conclusion, not all participants had detectable S1 IgG antibodies. The Ad5-nCoV vaccine presented the most seronegative cases. The studied vaccines were shown to be safe.

COVID-19 vaccination for patients with benign childhood epilepsy with centrotemporal spikes

“…Of the 16 of 77 (20.78%) patients vaccinated with CanSino: Ad5-nCoV vaccine, among local side effects, only one (6.25%) parent reported pain at the injection site, and as for systematic side effects, they reported headache (6.25%), dizziness (12.50%), fatigue (12.50%), and decreased appetite (12.50%). These parameters were lower than those reported by a study in Mexico, wherein pain at the injection site (48.1%), redness at the injection site (3.7%), swelling (3.7%), fatigue (50%), fever (16.7%), and headache (25.9%) were the presentations [22] . In clinical trials involving adults, the most reported local side effect was pain at the injection site (54%), and the most reported systemic side effects were fever (46%), fatigue (44%), headache (39%), and muscle pain (17%).…”

Factors Influencing Level and Persistence of Anti SARS-CoV-2 IgG after BNT162b2 Vaccine: Evidence from a Large Cohort of Healthcare Workers

“…with 99.8% of vaccine antibody response [ 7 ]. In other studies on general population, IgG antibody generation following Pfizer/BioNTech vaccine was similarly high, ranging from 94.2% to 98.36% [ 8 , 9 ]. Data on efficacy of BNT162b2 mRNA COVID-19 vaccine evidenced a 95% efficacy in preventing COVID-19 [ 10 ]; this efficacy was confirmed in the updated analysis up to 6 months after the administration of the second dose [ 11 ]; our preliminary results on breakthrough infections up to 4–5 months post-vaccination appear in line with these studies.…”

Clinical and Immunologic Efficacy of the Recombinant Adenovirus Type-5-Vectored (CanSino Bio) Vaccine in University Professors during the COVID-19 Delta Wave

“…Only two studies have evaluated the efficacy of the CanSino vaccine in Mexican populations [ 18 , 19 ]. Our results are similar to another study, in which higher neutralizing antibodies were detected in CanSino-vaccinated individuals with previous infection compared to those without previous infection (median 98% vs. 72%, p < 0.0001) [ 19 ].…”

“…The assessment of anti-S1 IgG antibody generation in 61 people vaccinated with Pfizer/BioNTech and 54 people vaccinated with CanSino showed a higher seronegative percentage in participants vaccinated with CanSino (11.11% vs. 1.64% after Pfizer/BioNTech two-dose administration) [ 18 ]. In another study, 17 (7.4%) individuals without previous infection did not have the presence of neutralizing antibodies after the CanSino vaccination [ 19 ].…”